Literature DB >> 25236731

Pathological potential of astroglial purinergic receptors.

Heike Franke1, Peter Illes.   

Abstract

Acute brain injury and neurodegenerative disorders may result in astroglial activation. Astrocytes are able to determine the progression and outcome of these neuropathologies in a beneficial or detrimental way. Nucleotides, e.g. adenosine 5'-triphosphate (ATP), released after acute or chronic neuronal injury, are important mediators of glial activation and astrogliosis.Acute injury may cause significant changes in ATP balance, resulting in (1) a decline of intracellular ATP levels and (2) an increase in extracellular ATP concentrations via efflux from the intracellular space. The released ATP may have trophic effects, but can also act as a proinflammatory mediator or cytotoxic factor, inducing necrosis/apoptosis as a universal "danger" signal. Furthermore, ATP, primarily released from astrocytes, is a means of communication between neurons, glial cells, and intracerebral blood vessels.Astrocytes express a heterogeneous battery of purinergic ionotropic and metabotropic receptors (P2XRs and P2YRs, respectively) to respond to extracellular nucleotides.In this chapter, we summarize the contemporary knowledge on the pathological potential of P2Rs in relation to changes of astrocytic functions, determined by distinct molecular signaling cascades, in a variety of diseases. We discuss specific aspects of reactive astrogliosis, with respect to the involvement of prominent receptor subtypes, such as the P2X7 and P2Y1/2Rs. Examples of purinergic signaling of microglia, oligodendrocytes, and blood vessels under pathophysiological conditions will also be presented.The understanding of the pathological potential of purinergic signaling in "controlling and fine-tuning" of astrocytic responses is important for identifying possible therapeutic principles to treat acute and chronic central nervous system diseases.

Entities:  

Year:  2014        PMID: 25236731     DOI: 10.1007/978-3-319-08894-5_11

Source DB:  PubMed          Journal:  Adv Neurobiol


  5 in total

1.  Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease.

Authors:  Hongjun Jin; Junbin Han; Derek Resing; Hui Liu; Xuyi Yue; Rebecca L Miller; Kathleen M Schoch; Timothy M Miller; Joel S Perlmutter; Terrance M Egan; Zhude Tu
Journal:  Eur J Pharmacol       Date:  2017-12-07       Impact factor: 4.432

Review 2.  Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis.

Authors:  Paola Nobili; Weida Shen; Katarina Milicevic; Jelena Bogdanovic Pristov; Etienne Audinat; Ljiljana Nikolic
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

3.  Astroglial Ca2+-Dependent Hyperexcitability Requires P2Y1 Purinergic Receptors and Pannexin-1 Channel Activation in a Chronic Model of Epilepsy.

Authors:  Mario Wellmann; Carla Álvarez-Ferradas; Carola J Maturana; Juan C Sáez; Christian Bonansco
Journal:  Front Cell Neurosci       Date:  2018-11-23       Impact factor: 5.505

4.  Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models.

Authors:  Wolfgang Fischer; Heike Franke; Ute Krügel; Heiko Müller; Klaus Dinkel; Brian Lord; Michael A Letavic; David C Henshall; Tobias Engel
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

5.  BAC transgenic mice to study the expression of P2X2 and P2Y1 receptors.

Authors:  Heike Franke; Ralf Hausmann; Marcus Grohmann; Michaela Schumacher; Janka Günther; Stefan M Singheiser; Tanja Nußbaum; Florian Wildner; Zoltan Gerevich; Ronald Jabs; Daniela Hirnet; Christian Lohr; Peter Illes; Günther Schmalzing
Journal:  Purinergic Signal       Date:  2021-05-28       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.